In this open-label study (NCT02142920), we investigated the distribution, pharmacokinetics, and metabolism of the pan-class-I isoform phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor gedatolisib (PF-05212384), following a single intravenous administration in healthy male subjects. A single, 89-mg, intravenous dose of gedatolisib was associated with a favorable safety profile in the 6 healthy subjects evaluated. Peak plasma concentrations for unchanged gedatolisib and total radioactivity were observed at the end of the 30-minute infusion. The only observed drug-related material in plasma was the parent drug, gedatolisib. Terminal half-life for plasma gedatolisib was ß37 hours. Following the dose, 66%-73% of drug-related material was recovered in the feces. Metabolism of gedatolisib was trace; only 1 oxidative metabolite, M5, was identified in feces (<1% of total dose). Identification of gedatolisib in feces suggests that biliary and/or intestinal secretion of unchanged parent drug significantly contributes to gedatolisib clearance.
The phosphatidylinositol 3-kinase (PI3K) pathway is commonly deregulated in cancer. Several alterations may lead to activation of this pathway, including mutation or amplification of PIK3CA, mutation and loss of function of PTEN, mutation of AKT, and overexpression or mutation of the receptor tyrosine kinase. Importantly, in cancer cells, aberrant activation of the PI3K pathway may represent a mechanism of resistance to treatment with tyrosine kinase inhibitors or chemotherapeutic agents. [1] [2] [3] Gedatolisib (PF-05212384) is an intravenous, adenosine triphosphate-competitive, highly selective, and potent pan-class I isoform PI3K and mammalian target of rapamycin inhibitor with a half-maximal inhibitory concentration (IC 50 ) of 0.4 nM for p110α, 6 nM for p110β, 6 nM for p110γ , 8 nM for p110δ, and 1 nM for mammalian target of rapamycin. 4, 5 It is intended to be dosed once weekly by a 30-minute intravenous (IV) infusion. In phase I and II clinical studies, gedatolisib has demonstrated a favorable safety profile and antitumor activity in patients with locally advanced or metastatic solid malignancies. [5] [6] [7] [8] [9] The optimal dose and regimen for the treatment of patients with advanced cancer have yet to be determined. The genetic complexity of most human cancers suggests that blockade of a single target or pathway essential for tumor cell proliferation is unlikely to produce sustained growth inhibition. Thus, blockade of multiple growth control mechanisms by different drugs may be necessary to optimize the success of treatment with molecularly targeted anticancer agents. 10, 11 Avoiding coadministration of agents that act as drug-metabolizing enzyme cosubstrates, inducers, or inhibitors may facilitate optimal responses, while minimizing adverse effects in treated patients due to interfering drug biotransformation and elimination pathways. 12 Studies on drug-metabolizing enzymes (i.e., cytochrome P450) and drug-drug and drug-food interactions are an important part of drug research and development. Recent case reports of serious reactions due to inappropriate, concomitant administration of certain drugs indicate that the development of novel agents and regimens requires careful consideration. 12 In addition, patients on multidrug regimens necessitate a thorough review of each combination with respect to drug biotransformation. 13 The exact pathways responsible for the clearance of gedatolisib are currently unknown. The objectives of the clinical study were to investigate the metabolism and excretion of [ 14 C]gedatolisib; to characterize plasma, fecal, and urinary radioactivity; and to identify any circulating or excreted metabolites, following a single-dose IV infusion of [ 14 C]gedatolisib 89 mg. Due to the common comorbidities and frequent coadministration of other medications in cancer patients, which may compromise a clear understanding of drug metabolism, this study was conducted in healthy male volunteers.
In order to more clearly define the hepatobiliary transport of gedatolisib, we used the sandwich-cultured human hepatocyte (SCHH) model as an in vitro tool used to measure hepatobiliary transport and assess both uptake and biliary efflux, to aid in the interpretation of clinical results. 14, 15 This method allows measurement of the apparent in vitro intrinsic biliary clearance (CL app ).
Methods Materials
For in vitro studies, gedatolisib was synthesized at Pfizer; rosuvastatin and rifamycin SV were purchased from Sequoia Research Products (Pangbourne, Berkshire, United Kingdom) and Sigma (St. Louis, Missouri), respectively. InVitroGRO-HT, CP and HI, were purchased from Celsis In Vitro Technologies, Inc (Baltimore, Maryland). Hanks' balanced salt solution (HBSS), both Ca 2+ /Mg 2+ -containing and -free, were obtained from Lonza (Portsmouth, New Hampshire). Biocoat 24-well plates and Matrigel TM were purchased from BD Biosciences (San Jose, California). BCA protein assay kit was purchased from Pierce Biotechnology (Rockford, Illinois), radioimmunoprecipitation assay buffer from TEKnova (Hollister, California), and cryopreserved hepatocytes (lot HH1025) from In Vitro ADMET laboratories (Columbia, Maryland).
Sandwich-Cultured Human Hepatocyte Model
Preparation of SCHH. Cryopreserved human hepatocytes were thawed and plated as described previously. 16 Briefly, cryopreserved human hepatocytes were thawed in a water bath at 37°C and placed on ice. The cells were then poured into 37°C InVitroGRO-HT medium at a ratio of 1 vial/50 mL in a conical tube, centrifuged at 50g for 3 minutes, and resuspended to 0.75 × 10 6 cells/mL in InVitroGRO-CP medium. Cell viability was determined by trypan blue exclusion. On day 1, the hepatocyte suspensions were plated on collagen-coated 24-well plates at a density of 0.375 × 10 6 cells/well in a volume of 0.5 mL/well. After 18 to 24 hours of incubation at 37°C in 5% CO 2 , the cells were overlaid with ice-cold 0.25 mg/mL BD Matrigel Matrix Phenol RedFree in incubation medium at 0.5 mL/well. The cultures were maintained at 37°C in 5% CO 2 in InVitroGRO-HI, which was replaced every 24 hours.
Sandwich-Cultured Human Hepatocyte Assay Procedure. The determination of hepatic disposition in SCHH was conducted as described previously. 17 On day 5 of SCHH, the hepatocytes were rinsed twice with Ca 2+ /Mg 2+ -containing (standard) or -free HBSS buffer and preincubated for 10 minutes at 37°C with standard HBSS buffer in the absence or presence of 100 μM rifamycin SV, or Ca 2+ /Mg 2+ -free HBSS buffer alone. After aspirating the preincubation buffer, 0.5 mL of incubation buffer, containing the test compound or rosuvastatin at 1 μM, was added in the absence or presence of rifamycin SV. The assay was terminated at 0.5, 1, 2, 5, 10, and 15 minutes by removal of the incubation buffer, followed by adding 0.5 mL of ice-cold standard HBSS buffer. The cells were then quickly washed 3 times with 0.5 mL of ice-cold standard HBSS buffer. The hepatocytes were lysed by methanol-containing internal standard and 10-μL aliquots were injected onto the liquid chromatography-mass spectrometry (LC-MS/MS) system. Protein concentration of SCHH was determined by the BCA protein assay kit by lysing cells with 0.5 mL/well of radioimmunoprecipitation assay buffer. Total CL app and passive CL app were obtained from an initial rate analysis with a linear fit up to 5 minutes. Biliary CL app was calculated at 10 minutes as described previously. 
Study Design and Participants
This open-label, distribution, metabolism, and pharmacokinetic (PK) study of gedatolisib was conducted in 6 healthy male subjects at a single center (Quotient Clinical Research Unit, Nottingham, United Kingdom). It was approved by an institutional review board (Research Ethics Committee for Wales, Cardiff, United Kingdom), and it followed the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All subjects provided voluntary, written informed consent. The study was sponsored by Pfizer and registered at ClinicalTrials.gov (NCT02142920).
Healthy male subjects (aged 30-65 years) were included in the study if they had a body mass index of 17.5-30.5 kg/m 2 , a total body weight >50 kg (110 lb), and had been vasectomized or were using an adequate method of contraception (for the duration of the active treatment period and at least 90 days after the last dose of study drug). Healthy was defined as having no clinically relevant abnormalities identified by a detailed medical history and full physical examination, including blood pressure and pulse rate measurement, 12-lead electrocardiogram, and clinical laboratory tests.
Subjects were excluded from this study if they had a history of prior clinically significant disease; a positive urine drug screen or history of drug/alcohol abuse in the previous 2 years; excessive alcohol consumption (>21 units/week) within 6 months prior to screening; prior treatment with an investigational drug within 90 days or 5 half-lives preceding the first dose of study drug; prior enrollment in a radionucleotide study; or prior radiation therapy (within 12 months of study entry) or prior exposure to radiation (i.e., diagnostic X-rays and other medical exposures exceeding 5 millisieverts in the previous 12 months or 10 millisieverts in the previous 5 years).
Further, subjects were excluded if they were smokers or had used tobacco or nicotine-containing products within the previous 12 months; had confirmed supine blood pressure ࣙ140 mm Hg (systolic) or ࣙ90 mm Hg (diastolic) and a corrected QT interval >450 milliseconds at screening; did not normally open their bowels daily or exceeded 3 bowel movements per day; were positive for hepatitis B surface antigen, hepatitis C virus antibody, or HIV infection; had given a blood donation of ß400 mL within 3 months prior to dosing; or had a history of serious adverse reaction or serious hypersensitivity to any drug or formulation excipients.
Study Treatment
Following an overnight fast of ࣙ8 hours, subjects received a ß30-minute IV infusion of [ 14 C]gedatolisib 89 mg at ß08:00 (± 2 hours). The selection of the 89-mg dose was based on observations in the initial phase I study, in which 89 mg was the highest dose tested where none of the patients (n = 4) treated at this dose level had experienced dose-limiting toxicity or treatment-related, grade ࣙ3 adverse events (AEs). 
Pharmacokinetic Evaluations and Calculation of PK Parameters
The following PK end points were evaluated during the study: (1) cumulative recovery (%) of radioactivity in feces and urine; (2) for plasma gedatolisib: maximum concentration (C max ), time to maximum concentration (T max ), area under the concentration-time profile from time 0 to the time of the last quantifiable concentration (AUC last ), area under the concentration-time profile from time 0 extrapolated to infinite time (AUC inf ), terminal half-life (t ½ ), systemic clearance (CL), steadystate volume of distribution (V ss ), and volume of distribution during terminal phase (V d,area ); (3) for plasma [ 14 C]gedatolisib radioactivity: C max , T max , AUC last , AUC inf , t ½ , CL, V ss , and V d,area ; and (4) for urine gedatolisib: total amount and percentage of total drug excreted unchanged in the urine, and renal clearance (CL r ).
PK parameters were calculated for plasma gedatolisib, plasma radioactivity, and urine gedatolisib for each subject, using noncompartmental analysis of plasma and urine concentration-time data. Samples below the lower limit of quantification (LLOQ) were set to 0 and actual sample collection times were used for the analyses.
Plasma, Urine, and Feces Sampling
Three types of samples were collected and analyzed for gedatolisib total radioactivity, PK, and metabolite identification: blood processed to plasma, urine, and feces.
Plasma Sampling for Radioactivity Measurement, PK Analysis, and Metabolite Profiling. Blood samples for PK analysis were collected on days 1 through 9 into appropriately labeled tubes containing K 2 ethylenediaminetetraacetic acid as the anticoagulant. Blood samples were taken at 0 (predose), 0.5 (immediately before the end of the gedatolisib infusion), and at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, and 192 hours. Subjects remained in the research facility until 1 of the following requirements had been met: the amount of radioactivity recovered in excreta was ࣙ90% of administered radioactivity or <1% had been recovered in excreta from 2 consecutive days (i.e., total for urine plus feces should have been <1% on 2 consecutive days). For subjects not meeting the above criteria on or beyond day 9, blood samples for gedatolisib PK analysis, radioactivity quantitation, or metabolite identification were taken every 24 hours.
Urine Sample Collection for Radioactivity Measurement, PK Analysis, and Metabolite Profiling. Urine samples were collected prior to dosing ("blank"), at 0 to 4, 4 to 8, 8 to 12, and 12 to 24 hours after start of infusion, and then at 24-hour intervals until end of the study. Each subject emptied his bladder just prior to dosing and a 10-mL aliquot from this urine ("urine blank") was labeled and frozen at -20°C. After each urine void, the weight of the collected urine sample was measured and the sample was mixed with a 3% CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate) solution by weight. The individual urine samples were pooled into a single container for each collection interval and stored at 4°C until aliquoted for each planned analysis. The sample aliquots were labeled, frozen at approximately -20°C, and shipped on dry ice to the selected laboratories for analysis.
Fecal Sample Collection for Radioactivity Measurement and Metabolic Profiling. A fecal sample was collected from each subject from time of admission until predose (blank). Following dosing, feces were collected as passed in 24-hour intervals through the end of the study. Fecal samples were stored at -20°C until the end of each collection period. For subjects not meeting the radioactivity excretion levels defined above on day 9, fecal collection (one collection for each 24-hour period) was continued beyond day 9 and up to a maximum of day 14.
Pharmacokinetic Analytical Methods
Plasma Gedatolisib. Plasma samples were analyzed for gedatolisib concentrations at inVentiv Health Clinical Lab (Princeton, New Jersey) using a validated, sensitive, and specific high-performance liquid chromatography (HPLC)-MS/MS method. A 100-μL aliquot of K 2 ethylenediaminetetraacetic acid plasma was fortified with 20 μL of 200 ng/mL 50:50 methanol:water working solution of d 4 -WYE-129587 used as an internal standard. One hundred microliters of carbonate buffer (pH10) was added and the analyte was isolated through liquid-liquid extraction using 1000 μL of methyl-t-butyl ether (MTBE). Approximately 975 μL of the MTBE extract were transferred to a new vial, evaporated to dryness under nitrogen flow at 40°C, and reconstituted in 100 μL of methanol:water solution. An aliquot of the reconstituted extract (5-40 μL) was injected onto an HPLC-MS/MS equipped with Agilent 1100 LC system, using a Water Atlantis dC18 2.1 × 30 mm HPLC column and gradient elution (0.1% formic acid in water [mobile phase A] and 0.1% formic acid in 80:20 methanol:acetonitrile [mobile phase B]) at 0.4 mL/min flow rate. Samples were assayed for gedatolisib using positive ion electrospray mode on a AB Sciex API4000 TM mass spectrometer. The MRM ion pair was used to monitor gedatolisib and the internal standard. The mass to charge ratio (m/z) values used to monitor gedatolisib and internal standard were 616.6/488.2 and 620.6/492.2, respectively. Plasma specimens were stored at approximately -20°C until analysis and assayed within the 816 days of established stability. Calibration standard responses were linear over the range of 2 to 2000 ng/mL using a weighted (1/concentration 2 ) linear least squares regression. Samples with concentrations above the upper limits of quantification were adequately diluted into calibration range.
The LLOQ for gedatolisib in plasma was 2.00 ng/mL. The between-day assay accuracy, expressed as percentage relative error, for quality control (QC) concentrations, ranged from -3.33% to 1.00% for the low, medium, high, and diluted QC samples. Assay precision, expressed as the between-day percent coefficients of variation of the mean estimated concentrations of QC samples was ࣘ4.98% for low (6.00 ng/mL), medium (100 ng/mL), high (1500 ng/mL), and diluted (10,000 ng/mL) concentrations.
Urine Gedatolisib. Urine samples were analyzed for gedatolisib concentrations at inVentiv Health Clinical Laboratory (Princeton, New Jersey) using a validated, sensitive, and specific HPLC-MS/MS method. Since the incurred urine samples were modified with 3% CHAPS during sample collection at the clinical site to minimize nonspecific binding to the tubes and a loss of the gedatolisib analyte, the calibrators and quality control samples prepared for gedatolisib analysis in the urine were also modified with 3% CHAPS during sample preparation for analysis, to match the matrix. A 50-μL aliquot of urine sample was fortified with 20 μL of 2000 ng/mL 50:50 methanol:water working solution of d 4 -WYE-129587 used as internal standard, 50 μL of carbonate buffer (pH10) was added, and the analyte was isolated through liquid-liquid extraction using 1000 μL of MTBE. Approximately 975 μL of the MTBE extract were transferred to a new vial, evaporated to dryness under nitrogen flow at 40°C, and reconstituted in 100 μL of methanol:water solution. An aliquot of the reconstituted extract (5 to 40 μL) was injected onto an HPLC-MS/MS equipped with Agilent 1100 LC system using a Water Atlantis dC18 2.1 × 30 mm HPLC column and gradient elution (0.1% formic acid in water [mobile phase A] and 0.1% formic acid in 80:20 methanol:acetonitrile [mobile phase B]) at 0.4 mL/min flow rate. Samples were assayed for gedatolisib using positive ion electrospray mode on a AB Sciex API4000
TM mass spectrometer. The MRM ion pair was used to monitor gedatolisib and the internal standard. The mass to charge ratio (m/z) values used to monitor gedatolisib and internal standard were 616.6/488.2 and 620.6/492.2, respectively. Urine samples were stored at approximately -20°C until analysis and assayed within the 136 days of established stability data generated during validation. Calibration standard responses were linear over the range of 20.0-20,000 ng/mL, using a weighted (1/concentration 2 ) linear least squares regression. The LLOQ for urine gedatolisib was 20.0 ng/mL. The between-day assay accuracy, expressed as percentage relative error, for QC concentrations, ranged from 0.667% to 2.67% for the low, medium, high, and diluted QC samples. Assay precision, expressed as the between-day %CV of the mean estimated concentrations of QC samples, was ࣘ4.77% for low (60.0 ng/mL), medium (1000 ng/mL), and high (15, Radioactivity in urine, plasma, and dose solution was quantified directly by LSC using a liquid scintillation counter with automatic, external, standard quench correction. Samples were mixed with scintillant (Ultima Gold XR) and counted (2300TR TriCarb R , Scintillation Counter; Perkin Elmer). Detected counts per minute were converted to disintegrations per minute using quench correction. The quench curves were developed using standards purchased from Perkin Elmer Life and Analytical Sciences, and prepared from stock solutions calibrated against the National Institute of Standards and Technology Reference Materials. The validity of the curves was checked regularly. The LLOQs using LSC were defined as twice the background disintegrations per minute values. Resulting LLOQ values were 0.01 (urine), 0.06 (feces), and 0.07 (plasma) μg Eq/g (mL).
Metabolic Profiling Sample Extraction and Analysis of Gedatolisib Drug-Related
Material for Metabolic Profiling. Urine samples were pooled from 0 to 72 hours based on percent mass excreted for all subjects. The mean pooled sample represented 91.5% of total urinary radioactivity. Pooled urine samples were concentrated 20× using a Genevac EZ-2 evaporative centrifuge (Genevac Inc., Valley Cottage, New York) followed by 2-fold dilution with 5% acetonitrile in water. Particulates were removed by centrifugation at 1800g for 5 minutes before HPLC-MS/MS analysis. Fecal homogenate samples from 0 to 168 hours were based on percent mass excreted for all subjects. The mean pooled sample represented 96.7% of total fecal radioactivity. Aliquots (2 g) of fecal pools were diluted with acetonitrile (30 mL), vortex-mixed (5 minutes), sonicated (30 minutes), and centrifuged (1800g for 10 minutes). The resulting supernatants were transferred to a clean 50-mL polypropylene centrifuge tube. The remaining fecal pellets were extracted a second time with 50:50 acetonitrile:1% formic acid. The first and second fecal pool extracts for each subject were combined and eluted through a Waters Sep-Pak Vac 20 cc (5 g) C18 cartridge collecting the eluent. The combined mean recovery of radioactivity after solid-phase extraction was 97.3%. The supernatants were concentrated by vacuum centrifugation and samples were diluted with acetonitrile to a final volume of 1.0 mL for HPLC-MS/MS analysis. Plasma samples, collected from each subject at 0.5, 1, 2, 4, 6, 8, and 12 hours after dose, were pooled to provide average AUC values from 0 to 12 hours for the parent and metabolite profile. The pooled plasma samples (3.92 mL) were diluted with 10 mL of acetonitrile, vortex-mixed, sonicated (5 minutes), and centrifuged (1800g; 5 min). The supernatants were concentrated to ß0.1 mL by vacuum centrifugation. Residues were diluted to a final volume of 200 μL with 20% acetonitrile in water.
Profiling of Excreta and Plasma by HPLC-MS With Radiometric Analysis. Urine, fecal homogenate extracts, and plasma extracts were analyzed by HPLC-MS/MS with fraction collection for radiometric analysis. The HPLC system consisted of an Accela quaternary solvent delivery pump, an Accela autoinjector, a Surveyor PDA Plus photodiode array detector (Thermo Electron Corporation, Asheville, North Carolina). Chromatography was performed on a Phenomenex Luna C18 (2) column (4.6 × 150 mm, 3 μm). The mobile phase was composed of 5-mM ammonium acetate (solvent A) and acetonitrile (solvent B) at a flow rate of 0.5 mL/min. The conditions were begun at 5%B, held for 5 minutes, followed by a linear increase to 70%B at 70 minutes, and a second linear increase to 95%B at 85 minutes. This condition was held for 5 minutes, followed by reequilibration of the column for 3 minutes. Approximately 10% of the post column flow was split to the mass spectrometer. Identification of the drug-related entities was performed on a Thermo Orbitrap mass spectrometer (Thermo Scientific, Waltham, Massachusetts) operating in positive ion electrospray mode. Full scan data and data-dependent product ion scans of the 3 most intense ions found in the full scan were obtained at 15 000 resolution. The remainder of the flow was split to a LEAP PAL HTS-xt fraction collector (LEAP Technologies). For fecal homogenates, fractions were collected every 15 seconds into 96-well scintiplates, while for urine and plasma samples, fractions were collected every 30 seconds into 24-well scintiplates. Scintillation fluid was added to the plates for analysis of carbon-14.
Safety Evaluations
The safety end points included laboratory tests, physical examination, vital signs, electrocardiograms, and safety monitoring. AEs were characterized by type, frequency, and relationship to study drug, and graded for severity (i.e., mild, moderate, or severe).
Results
The results from our in vitro investigations did not indicate a substantial active hepatic uptake for gedatolisib in the absence and presence of rifamycin SV, which is a pan-organic, anion-transporting polypeptide inhibitor, but showed biliary excretion for gedatolisib under the test conditions used in the SCHH model (Table  1 and Figure 1 ). The positive control, rosuvastatin, exhibited an uptake clearance, percentage of active uptake, and biliary excretion within the expected ranges. Although this study showed no contribution of active uptake for gedatolisib, biliary clearance was observed in the human hepatocyte system. Apparent in vitro biliary clearance from SCHH (biliary CL app = 0.84 μL/min/mg protein) was scaled to 0.82 L/h as an in vivo blood basis biliary clearance using the wellstirred hepatocyte model (unbound plasma fraction [fu p ] = 0.017; blood-to-plasma ratio [BPR] = 0.87; %CV, percent coefficient of variation; AUC inf , area under the plasma-concentration time profile from time 0 extrapolated to infinite time; AUC last , area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration; CL, clearance; C max , maximum observed plasma concentration; PK, pharmacokinetic; SD, standard deviation; t ½ , terminal half-life; T max , time for C max ; V ss , steady-state volume of distribution. a Arithmetic mean ± SD [geometric mean (geometric %CV)] for all parameters except: median (range) for T max ; arithmetic mean ± SD for t ½ . b Units for radioactivity parameters are ng Eq/mL (C max ) or ng Eq • h/mL (AUC).
unbound hepatocyte fraction [fu hep ] = 0.21). Based on the reported plasma clearance of 10.68 L/h (Table 2) , gedatolisib biliary clearance via active transport, determined in the in vitro SCHH model, is estimated to contribute ß8% of the total reported gedatolisib human clearance (Table 1 ).
In the clinical study, a total of 6 subjects were screened and received treatment with gedatolisib. All subjects were men with a mean age of 45 years (range 40-57 years), and the majority were white (n = 4, 66.7%). None of the subjects were discontinued from the study. The excretion of [ 14 C]gedatolisib and drugrelated material was studied in all 6 subjects. Urine and feces samples were collected until a maximum of 312 hours after dose administration. In the postdose collection period (up to 312 hours), 11.53% to 14.75% of administered radioactivity (AR) was excreted in the urine. Most of the drug-related material in the urine was recovered within the first 4 hours following dose administration. Maximum concentrations were observed at 0 to 4 hours. In the postdose collection period (up to 312 hours), 66.43% to 73.04% of AR was recovered in the feces. Most of the drug-related material in the feces was recovered within 120 hours. Maximal concentrations in feces samples were seen at time points from 24-48 hours to 96-120 hours. The total recovery (urine plus feces) from each of the subjects was in the range of 80.45% to 85.07% of AR. Cumulative median urine, feces, and total (urine plus feces) excretion data are presented in Figure 2 .
Plasma samples were analyzed for radioactivity concentrations by LSC and AMS methods. For the LSC method, radioactivity concentrations were below the LLOQ in all samples collected at 24 hours or later. For the AMS method, radioactivity concentrations were quantifiable in samples as late as 288 hours; therefore, all PK analyses of plasma radioactivity were based on the more sensitive AMS method. Median concentration-time profiles for gedatolisib and total radioactivity ([ 14 C]gedatolisib equivalents) in plasma are presented in Figure 3 . Median concentrations of total radioactivity were slightly higher than those for gedatolisib at all time points. Both profiles are otherwise similar, with the highest concentrations in the nominal 30-minute sample at the end of the IV infusion, a rapid initial decrease over the first 4 to 6 hours, and a much slower decline over the following 1 to 2 weeks. Plasma PK parameters are summarized descriptively in Table 2 and ratios of plasma gedatolisib to plasma total radioactivity for C max , AUC inf , and AUC last are presented in Table 3 . Consistent with the mean concentration-time profiles in Figure 3 , C max was observed at the end of the 30-minute infusion (T max 0.5 hours) for both total radioactivity and unchanged gedatolisib. Ratios of gedatolisib to total radioactivity were 0.8167 for C max and 0.6965 for AUC inf , indicating that unchanged gedatolisib accounted for ß82% of the peak radioactivity and ß70% of the total radioactivity in plasma. Apparent t ½ for total radioactivity in plasma (mean 126 hours) was >3 times longer than the terminal t ½ for gedatolisib (mean 37 hours); however, this longer apparent t ½ did not contribute significantly to the AUC inf for total radioactivity as the percentage of extrapolated AUC was <6%. Variability in plasma C max and AUC inf (based on geometric coefficient of variation) was 17% to 20% for both gedatolisib and total radioactivity. PK parameters for gedatolisib in urine are summarized in Table 4 was within approximately 2-fold of the observed total clearance in human (5.0 L/hr for a 70-kg subject vs 10.68 L/hr, respectively). The major drug-related entity observed in all matrices was unchanged gedatolisib, with a retention time of ß43 minutes ( Figure S1 ). Mass spectral data were consistent with this identification and showed a protonated molecular ion at m/z 616.3354 and fragment ions at m/z 488.2033 and 369.1664 (Figure 4) . One metabolite was identified in fecal homogenates from 2 of the 6 subjects at <1% of the total dose. It had a retention time of ß35 minutes on HPLC and showed a protonated molecular ion at m/z 634.3460 (Figure 4) , indicating the addition of 1 oxygen and 2 hydrogen atoms to the parent drug. Its product ion spectrum of the diprotonated molecular ion, which was most abundant at m/z 317.6760, showed diagnostic fragment ions at m/z 295.1471 and 253.6106 that are consistent with M5 arising from opening of the morpholine ring to the dihydroxy species 1-(4-(4-(bis(2-hydroxyethyl)amino)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(4-(4-(dimethylamino)piperidine-1-carbonyl)phenyl)urea (Figure 4 ). In the same 2 subjects where M5 was observed in feces, 2 other minor, unidentified metabolites were detected in urine (<2% of dose). The metabolite profiles in urine, feces, and plasma all had unchanged parent as the only major drug-related radioactive peak.
Five subjects experienced 16 treatment-emergent AEs (TEAEs), of which 12 were considered treatmentrelated by the investigator. All TEAEs were mild in severity. There were no severe AEs, serious AEs, or deaths during this study, and no permanent or temporary discontinuations due to AEs. Two laboratory test abnormalities were reported: 1 subject had urine glucose values that met the primary abnormality criteria (urine glucose [qualitative] ࣙ1) and 1 subject had urine protein values that met the secondary abnormality criteria (urine protein [qualitative] ࣙ1 and the subject's baseline value was outside the reference range). None of the laboratory findings were considered clinically significant by the investigator or reported as an AE. None of the changes in blood pressure, pulse rate, or electrocardiogram results were considered clinically significant.
Discussion
The objectives of this study were to characterize the primary route(s) of elimination of gedatolisib and drug-related material; estimate the overall recovery of radiolabeled material in humans; characterize the PK of gedatolisib and total AR; identify the metabolites of gedatolisib in plasma, urine, and/or feces, if possible; and characterize the safety of a 89-mg single dose of [
14 C]gedatolisib (ß60 μCi) administered to healthy male volunteers.
Urinary excretion, as measured by radioactivity analysis, was found to be a minor route of elimination, with 12% to 15% of the dose excreted in the urine over the 312-hour collection period. This is similar to ß13% of the dose recovered in urine as unchanged gedatolisib, measured by LC-MS/MS. The mean CL r of gedatolisib was 1.4 L/h, which is higher than the product of glomerular filtration rate and fu p , indicating that active secretion may have a role in the renal clearance of gedatolisib. At 312 hours after dose administration, 66% to 73% of the dose was recovered in the feces. Most drug-related material in the feces was recovered within 120 hours. Total recovery in urine and feces for each of the subjects was in the range 81% to 85% of AR.
Peak plasma concentrations for both total radioactivity and unchanged gedatolisib were observed at the end of the 30-minute infusion. Based on ratios of gedatolisib to total radioactivity for C max and AUC inf , unchanged gedatolisib accounted for ß82% of the peak radioactivity and ß70% of the total radioactivity in plasma. As no drug-related material other than the parent drug was detected in the plasma and excreta samples, the difference in AUC of total radioactivity and plasma gedatolisib is likely due to the use of different analytical methods (radiometric vs HPLC-MS). PK parameters for parent gedatolisib in plasma were consistent with those reported after single-dose administration in the first-in-patient study conducted in patients with advanced solid tumors. 5 Metabolism of gedatolisib was trace, with the only identified metabolite being a ring-opened alcohol in feces (M5) representing a mean of 0.4% of the total dose. Two additional unknown metabolites were observed in the urine of 2 subjects, representing an overall mean of 0.2% and 0.3% of the total dose. The metabolite profiles in urine, feces, and plasma all had unchanged parent as the only major drug-related radioactive peak. Identification of gedatolisib in feces suggests that biliary and/or intestinal secretion of unchanged parent significantly contributes to drug clearance.
In vitro investigation of the transport in the SCHH model showed the capability of biliary transporters to act on gedatolisib, consistent with the observations of drug disposition in vivo. However, scaling the rate of transport from the in vitro hepatocyte system underestimated the observed total clearance, suggesting that the rate is underrepresented in the in vitro system or that intestinal secretion plays a larger role in secretion of intravenously administered gedatolisib into the feces.
Single IV doses of gedatolisib 89 mg were well tolerated in the healthy subjects evaluated in this study. Although most of the observed TEAEs were treatment related, all the TEAEs observed were mild in severity and there were no treatment discontinuations or delays due to TEAEs.
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